DE602005024437D1 - Mrt-geführte photodynamische therapie gegen krebs - Google Patents

Mrt-geführte photodynamische therapie gegen krebs

Info

Publication number
DE602005024437D1
DE602005024437D1 DE602005024437T DE602005024437T DE602005024437D1 DE 602005024437 D1 DE602005024437 D1 DE 602005024437D1 DE 602005024437 T DE602005024437 T DE 602005024437T DE 602005024437 T DE602005024437 T DE 602005024437T DE 602005024437 D1 DE602005024437 D1 DE 602005024437D1
Authority
DE
Germany
Prior art keywords
mri
photodynamic therapy
treatment
disclosed
laser energy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602005024437T
Other languages
German (de)
English (en)
Inventor
Zheng-Rong Lu
Anagha Viadya
Tianyi Ke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Utah Research Foundation Inc
Original Assignee
University of Utah Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Utah Research Foundation Inc filed Critical University of Utah Research Foundation Inc
Publication of DE602005024437D1 publication Critical patent/DE602005024437D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/146—Peptides, e.g. proteins the peptide being a polyamino acid, e.g. poly-lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Radiation-Therapy Devices (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Laser Surgery Devices (AREA)
DE602005024437T 2004-12-03 2005-12-02 Mrt-geführte photodynamische therapie gegen krebs Expired - Lifetime DE602005024437D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63325504P 2004-12-03 2004-12-03
PCT/US2005/044012 WO2006060797A2 (en) 2004-12-03 2005-12-02 Mri guided photodynamic therapy for cancer

Publications (1)

Publication Number Publication Date
DE602005024437D1 true DE602005024437D1 (de) 2010-12-09

Family

ID=36565853

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005024437T Expired - Lifetime DE602005024437D1 (de) 2004-12-03 2005-12-02 Mrt-geführte photodynamische therapie gegen krebs

Country Status (9)

Country Link
US (1) US20090076571A1 (enExample)
EP (1) EP1830879B1 (enExample)
JP (1) JP2008522666A (enExample)
KR (1) KR20070086803A (enExample)
AT (1) ATE485836T1 (enExample)
AU (1) AU2005311560A1 (enExample)
CA (1) CA2589881A1 (enExample)
DE (1) DE602005024437D1 (enExample)
WO (1) WO2006060797A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006322254B2 (en) 2005-12-05 2012-08-02 Nitto Denko Corporation Polyglutamate-amino acid conjugates and methods
US20080181852A1 (en) * 2007-01-29 2008-07-31 Nitto Denko Corporation Multi-functional Drug Carriers
CN101674852A (zh) * 2007-04-10 2010-03-17 日东电工株式会社 多功能聚谷氨酸盐药物载体
WO2008141110A2 (en) * 2007-05-09 2008-11-20 Nitto Denko Corporation Polyglutamate conjugates and polyglutamate-amino acid conjugates having a plurality of drugs
US20100284927A1 (en) * 2007-10-26 2010-11-11 University Of Utah Research Foundation Use of mri contrast agents for evaluating the treatment of tumors
US20120184495A1 (en) * 2009-06-12 2012-07-19 Amrita Vishwa Vidyapeetham University Kerala Targeted nano-photomedicines for photodynamic therapy of cancer
WO2013119957A1 (en) * 2012-02-10 2013-08-15 Aidan Research And Consulting, Llc Weight reduction through inactivation of gastric orexigenic mediator producing cells
TW201514188A (zh) * 2013-03-13 2015-04-16 Lantheus Medical Imaging Inc 製備釓磷維塞三鈉單水合物之方法
CN114870014B (zh) * 2022-05-18 2023-07-07 南京邮电大学 一种多功能抗肿瘤高分子药物及其制备方法和用途
WO2025160349A1 (en) * 2024-01-25 2025-07-31 Ovokaitys Todd Frank Methods and systems for improving photodynamic therapy by increasing depth of penetration without concurrently increasing energy deposition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5594136A (en) * 1989-12-21 1997-01-14 Pharmacyclics, Inc. Texaphyrin solid supports and devices
WO1998026747A2 (en) * 1996-12-17 1998-06-25 Terman David S Superantigen based methods and compositions for treatment of diseases
DE19831217A1 (de) * 1998-07-03 2000-01-05 Schering Ag Neue Porphyrinderivate, diese enthaltende pharmazeutische Mittel und ihre Verwendung in der photodynamischen Therapie und MRI-Diagnostik
US6534040B2 (en) * 1999-12-23 2003-03-18 Health Research, Inc. Chlorin and bacteriochlorin-based aminophenyl DTPA and N2S2 conjugates for MR contrast media and radiopharmaceuticals
WO2002087632A1 (en) * 2001-05-02 2002-11-07 Metaprobe, Inc. High throughput screening methods using magnetic resonance imaging agents

Also Published As

Publication number Publication date
AU2005311560A1 (en) 2006-06-08
WO2006060797A2 (en) 2006-06-08
EP1830879A4 (en) 2008-09-17
EP1830879B1 (en) 2010-10-27
JP2008522666A (ja) 2008-07-03
EP1830879A2 (en) 2007-09-12
KR20070086803A (ko) 2007-08-27
CA2589881A1 (en) 2006-06-08
WO2006060797A3 (en) 2006-08-24
ATE485836T1 (de) 2010-11-15
US20090076571A1 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
Zhang et al. NIR-II light in clinical oncology: opportunities and challenges
Dupont et al. INtraoperative photoDYnamic Therapy for GliOblastomas (INDYGO): study protocol for a phase I clinical trial
Beck et al. Interstitial photodynamic therapy of nonresectable malignant glioma recurrences using 5‐aminolevulinic acid induced protoporphyrin IX
Bechet et al. Photodynamic therapy of malignant brain tumours: A complementary approach to conventional therapies
Celli et al. Imaging and photodynamic therapy: mechanisms, monitoring, and optimization
Detappe et al. Advanced multimodal nanoparticles delay tumor progression with clinical radiation therapy
Meyers et al. Peptide‐targeted gold nanoparticles for photodynamic therapy of brain cancer
Allison Photodynamic therapy: oncologic horizons
Hirschberg et al. Disruption of the blood–brain barrier following ALA‐mediated photodynamic therapy
Bugaj Vascular targeted photochemotherapy using padoporfin and padeliporfin as a method of the focal treatment of localised prostate cancer-clinician’s insight
Kochneva et al. Photosensitizer Radachlorin®: Skin cancer PDT phase II clinical trials
US6083487A (en) Methylene blue and toluidene blue mediated fluorescence diagnosis of cancer
Zhang et al. Novel self‐assembled multifunctional nanoprobes for second‐near‐infrared‐fluorescence‐image‐guided breast cancer surgery and enhanced radiotherapy efficacy
Shackley et al. Light penetration in bladder tissue: implications for the intravesical photodynamic therapy of bladder tumours
Chin et al. Fluorescence imaging and phototoxicity effects of new formulation of chlorin e6–polyvinylpyrrolidone
Arumainayagam et al. Photodynamic therapy for focal ablation of the prostate
Vaidya et al. Contrast enhanced MRI‐guided photodynamic therapy for site‐specific cancer treatment
DE602005024437D1 (de) Mrt-geführte photodynamische therapie gegen krebs
Komolibus et al. Perspectives on interstitial photodynamic therapy for malignant tumors
Schaffer et al. Treatment of cervix carcinoma FIGO IIIb with Photofrin II as a radiosensitizer: a case report
Shliakhtsin et al. Pharmacokinetics and biodistribution of Photolon®(Fotolon®) in intact and tumor-bearing rats
Betrouni et al. An image guided treatment platform for prostate cancer photodynamic therapy
JP2008522666A5 (enExample)
Spangler et al. Optimization of targeted two-photon PDT triads for the treatment of head and neck cancers
RU2204426C1 (ru) Способ фотодинамической диагностики и терапии больных первично-множественным раком кожи